Multicenter, Randomized, Open-label Trial Comparing the Immunological Efficacy of a Vaccine Regimen Combining Two Covid19 mRNA Vaccines (Pfizer-BioNTech and Moderna) With That of a Homologous Vaccination of Each Covid19 mRNA Vaccine: Non-inferiority Trial
Latest Information Update: 06 Jul 2023
At a glance
- Drugs Elasomeran (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
- Acronyms ARNCOMBI
- 31 Jul 2021 Status changed from recruiting to active, no longer recruiting.
- 07 Jun 2021 Status changed from not yet recruiting to recruiting.
- 28 May 2021 New trial record